<DOC>
	<DOCNO>NCT01564823</DOCNO>
	<brief_summary>The present study objective evaluate Adalimumab efficacy versus Azathioprine efficacy prevention endoscopic recurrence ( Rutgeerts Index= 2b , 3 4 ) Crohn´s Disease patient 52 week treatment .</brief_summary>
	<brief_title>Adalimumab Preventing Post-chirurgic Recurrence Crohn´s Disease</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Age ≥ 18 year age time sign informed consent . Patients Crohn 's disease undergone ileocecal/ileocolic resection ( L1 L3 ) . The study treatment must initiate within two first week resection ( +/ 5 day ) . Patients surgical reconstruction ileocolic anastomosis . Women childbearing age must breastfeed must negative urine pregnancy test must agree use contraceptive method &lt; 1 % failure rate ( e.g. , sexual abstinence , oral contraceptive , double barrier method , intrauterine device ) , unless one partner sterile . Patients sign date informed consent form perform specific screen study procedure . Resection requieres Temporal ileostomy . Urgency resection doesn´t permit initial assessment protocol completion . Resection due inactive short indolent stenosis ( &lt; 10 cm ) . Resection mucosal macroscopic residual disease anastomosis . Previous intolerance adverse reaction ( moderate severe ) adalimumab azathioprine . Any contraindication unwillingness perform schedule colonoscopy resonance . Contraindications Adalimumab treatment , among follow include : active tuberculosis , severe infection sepsis opportunistic infection , moderate severe heart failure ( NYHA class III IV ) , central nervous system demyelinate disease , history malignant neoplasm autoimmune disease . Severe associate Extraintestinal manifestation . Previous postoperative recurrence prevention treatment adalimumab , asathiprine mercaptopurine result failure . Any disease patient condition accord investigator criterion , inadequates patient´s participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Crohn´s disease</keyword>
	<keyword>Metronidazole</keyword>
	<keyword>Azathioprine</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>post-chirurgic recurrence</keyword>
</DOC>